Last reviewed · How we verify
JK07
At a glance
| Generic name | JK07 |
|---|---|
| Sponsor | Salubris Biotherapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension (PHASE2)
- Study of JK07 in Patients With Chronic Heart Failure (PHASE2)
- Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) (PHASE1)
- Single-Ascending Dose Study of JK07 in Subjects With HFpEF (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JK07 CI brief — competitive landscape report
- JK07 updates RSS · CI watch RSS
- Salubris Biotherapeutics Inc portfolio CI